Torcetrapib + atorvastatin (Pfizer).
Pfizer is developing a combination tablet containing torcetrapib, a cholesteryl ester transfer protein inhibitor and high-density lipoprotein cholesterol enhancer, and the 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor, atorvastatin, for the potential treatment of atherosclerosis and hypercholesterolemia. As of April 2005, phase III trials were ongoing.